317 related articles for article (PubMed ID: 10768865)
1. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP
Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
[TBL] [Abstract][Full Text] [Related]
4. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
5. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
Xu F; Yu Y; Le XF; Boyer C; Mills GB; Bast RC
Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783
[TBL] [Abstract][Full Text] [Related]
6. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
Menendez JA; Mehmi I; Lupu R
Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820
[TBL] [Abstract][Full Text] [Related]
7. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
8. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
9. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
10. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
Tan M; Grijalva R; Yu D
Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
[TBL] [Abstract][Full Text] [Related]
11. Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells.
Ram TG; Kokeny KE; Dilts CA; Ethier SP
J Cell Physiol; 1995 Jun; 163(3):589-96. PubMed ID: 7775601
[TBL] [Abstract][Full Text] [Related]
12. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.
Aguilar Z; Akita RW; Finn RS; Ramos BL; Pegram MD; Kabbinavar FF; Pietras RJ; Pisacane P; Sliwkowski MX; Slamon DJ
Oncogene; 1999 Oct; 18(44):6050-62. PubMed ID: 10557094
[TBL] [Abstract][Full Text] [Related]
13. p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal.
Diehl KM; Grewal N; Ethier SP; Woods-Ignatoski KM
J Surg Res; 2007 Sep; 142(1):162-9. PubMed ID: 17612563
[TBL] [Abstract][Full Text] [Related]
14. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas.
Balañá ME; Lupu R; Labriola L; Charreau EH; Elizalde PV
Oncogene; 1999 Nov; 18(46):6370-9. PubMed ID: 10597237
[TBL] [Abstract][Full Text] [Related]
15. Src family kinases and HER2 interactions in human breast cancer cell growth and survival.
Belsches-Jablonski AP; Biscardi JS; Peavy DR; Tice DA; Romney DA; Parsons SJ
Oncogene; 2001 Mar; 20(12):1465-75. PubMed ID: 11313890
[TBL] [Abstract][Full Text] [Related]
16. Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.
Schaefer G; Fitzpatrick VD; Sliwkowski MX
Oncogene; 1997 Sep; 15(12):1385-94. PubMed ID: 9333014
[TBL] [Abstract][Full Text] [Related]
17. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.
Zhang L; Chang CJ; Bacus SS; Hung MC
Cancer Res; 1995 Sep; 55(17):3890-6. PubMed ID: 7543819
[TBL] [Abstract][Full Text] [Related]
18. Induction or suppression of expression of cytochrome C oxidase subunit II by heregulin beta 1 in human mammary epithelial cells is dependent on the levels of ErbB2 expression.
Sun Y; Lin H; Zhu Y; Ma C; Ye J; Luo J
J Cell Physiol; 2002 Aug; 192(2):225-33. PubMed ID: 12115729
[TBL] [Abstract][Full Text] [Related]
19. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration.
Xiong S; Grijalva R; Zhang L; Nguyen NT; Pisters PW; Pollock RE; Yu D
Cancer Res; 2001 Feb; 61(4):1727-32. PubMed ID: 11245489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
